Generic Manufacturers Should Be Liable For Inadequate Label Warnings, Government Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Solicitor General advises the Supreme Court not to take up a case involving failure-to-warn claims for the heartburn drug Reglan.
You may also be interested in...
Supreme Court To Hear Generic Drug Preemption Cases Against Advice Of Solicitor General
The court agreed to review three cases in which generic manufacturers of Reglan (metoclopramide) were held responsible for warning about the risk of tardive dyskinesia.
Supreme Court To Hear Generic Drug Preemption Cases Against Advice Of Solicitor General
The court agreed to review three cases in which generic manufacturers of Reglan (metoclopramide) were held responsible for warning about the risk of tardive dyskinesia.
Supreme Court Gets Nudge On Bayh-Dole Case; Denies HRT Petition; Will Review Infringement “State Of Mind”
The Solicitor General has urged the Supreme Court to take up a case questioning whether an inventor can eliminate a university’s rights to federally funded research by making an agreement with a third party.